Do you modify the duration of adjuvant therapy for patients with colon cancer who have undergone metastectomy and primary tumor resection?

For de novo oligometastatic colon cancer that is amenable to a potentially curative approach, I aim for 6 months of perioperative chemotherapy with fluoropyrimidine and oxaliplatin. Since irinotecan, anti-EGFR monoclonal antibodies, and bevacizumab do not treat micrometastatic disease effectively, they should be avoided in the postoperative setting if macroscopic metastatic disease is no longer present (even if they were used in the preoperative setting for some reason).